GHENT, Belgium, 17 August 2016 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] will report its 2016 half year financial results and year-to-date business update on Thursday 25 August 2016 at 7.00 am CET.

The Ablynx management team will host a conference call on Thursday 25 August 2016 at 4.00 pm CET/10.00 am ET, which will be webcast live and may be accessed by clicking here.

If you would like to participate in the Q&A session, please dial +32 (0)2 620 01 38 and use confirmation code 7155296.

Shortly after the call, a replay of the webcast and copy of the presentation will be available on the Ablynx website under http://www.ablynx.com/news/events-presentations/.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to creating new medicines which will make a real difference to society. Today, the Company has more than 40 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, immuno-oncology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Genzyme, Merck & Co., Inc., Merck KGaA, Novartis, Novo Nordisk and Taisho Pharmaceuticals. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact
Ablynx:
Dr Edwin Moses
CEO
t:   +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e:  edwin.moses@ablynx.com

Marieke Vermeersch
Director IR & Corporate Communications
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com
Follow us on Twitter @AblynxABLX

Ablynx media/analyst relations
FTI Consulting:
Julia Phillips, Brett Pollard, Mo Noonan, Matthew Moss
t: +44 20 3727 1000
e: ablynx@fticonsulting.com


pdf format of the press release


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire
HUG#2035092